Scott Glaser

We are thrilled to welcome two outstanding resident physicians to our team from 2027-2031. Happy match day! @cityofhope @ASTRO_org @TheNRMP #Match2026 #radonc

Advances in the planning and delivery of radiation treatments have come from efforts to simultaneously reduce negative effects in normal tissues and enhance tumor control (seen in figure). Learn more: nejm.org/doi/full/10.10…

Both our chief residents (@AriKassardjian1 and @Nick_Eustace) represented @cityofhope at #SABCS2025 presenting posters under the excellent mentorship of Jose Bazan MD. Excellent work!

Demo video from assembly to insertion for Aarhus applicator for cervical cancer youtu.be/pKn3v7yZ7R4 @AmericanBrachy @ACRORadOnc @ACRORadOnc @KamravaMD @MattHarkenrider @DocGlaser

Welcome @adapthyun !

On Monday, Sept 29th, we announced the activation of NRG-GY037, a pivotal Phase III randomized trial for patients with high-risk, locally advanced cervical cancer. PI: Jyoti Mayadev, MD @UCSDHealth Read more: conta.cc/3Iwh00d

Let’s talk #radonc during @ASTRO_org #ASTRO25. Join me and @ClaytonLadbury for a Meet & Greet session at the @cityofhope booth today!

Excited to be a social ambassador for @cityofhope during @ASTRO_org #ASTRO25. Catch my updates from the conference floor on X and LinkedIn!

Interested in #radonc? Join us for an open house September 24!

First Hybrid brachytherapy with Aarhus applicator in chicoutimi hospital, Quebec @AmericanBrachy on brachy awareness day @KamravaMD @DocGlaser @AndrewKellerMD

Congrats!

@DrSpratticus Interesting brachy had less urinary toxicity than EBRT. I typically counsel the reverse. Selection bias?

Despite RP + RT patients generally younger/healthier than RT patients (and very outdated RT), this observational non-randomized study shows RP+RT have highest risk of urinary adverse events. Important counseling for high risk PCa given trials consistently demonstrate ~80% will recur post RP. Valuable to use in clinic. @Soum_Roy_RadOnc @NicholasZaorsky @HimanshuNagarMD @AmarUKishan @ElishaFredman @TylerSbrt @DrAndrewLoblaw

Reassuring toxicity data from PCS IX trial after hypofractionated (5*5 Gy) pelvic & prostate #radiotherapy priori to #brachytherapy boost for #prostatecancer. #ESTRO25

STORM-PEACE V trial reported by @ZilliThomas #ESTRO25 Pelvic ENI superior to MDT for pelvic relapses after local Tx for #prostate cancer (6mo ADT each) Improves Biochemical PFS Locoregional PFS MFS ADT free survival Tox NS ENI clear SOC Online @TheLancetOncol Cc @piet_ost

Isotoxic FLAME shows 15% BCR difference with 10 years follow up with significant difference in local and regional recurrence #ESTRO2025 @AmarUKishan

Elective para-aortic RT + 24 months ADT shows promising results in pN1 prostate cancer! In the PART trial (n=96), 5y clinical RFS reached 91% in the adjuvant setting vs 63% salvage (p=0.029) with acceptable toxicity. Early intervention matters. #ESTRO2025 #RadOnc #ProstateCancer

Best #ESTRO2025 abstract for EMBRACE2 showing excellent locoregional control and significantly reduced morbidity compared to embrace 1 with tighter dose constraints with higher use of hybrid applicator ( new standard ) @KamravaMD @DocGlaser @AndrewKellerMD @AmericanBrachy

PLATO ACT 4 results for dose de-escalation in early-stage anal cancer are out! Prof Sebag-Montefiore presents on the plenary stage at #ESTRO24 3-year locoregional failure 16.4% for standard dose IMRT vs 12.4% reduced dose IMRT Reduced dose IMRT is safe & effective! #radonc

Danish data with longer follow up shows no difference in lymphedema or LRR with RNI hypofractionation @Icro_Meattini @ErinGillespieMD @DocGlaser @AndrewKellerMD #estro2025

So cool to see you improve cancer care around the world!